An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.
Markus WehlandUlf SimonsenNiels Henrik BuusMarcus KrügerDaniela GrimmPublished in: Expert opinion on pharmacotherapy (2020)
LCZ696 is effective in hypertension treatment. Short-term RCTs have shown that the highest doses of LCZ696 (200 and 400 mg [q.d.]) were more effective at lowering office and ambulatory blood pressure than angiotensin II receptor blockers (ARB) alone while having a similar tolerability profile. The effects of LCZ696 on hypertensive organ damage are only sparsely investigated and so far no studies have established the impact of LCZ696 on cardiovascular event rates. Future studies should focus on the comparison of LCZ696 and combination therapies already in use such as ARB and calcium channel blockers.
Keyphrases
- blood pressure
- angiotensin ii
- angiotensin converting enzyme
- arterial hypertension
- hypertensive patients
- oxidative stress
- vascular smooth muscle cells
- open label
- type diabetes
- clinical trial
- metabolic syndrome
- insulin resistance
- case control
- skeletal muscle
- adipose tissue
- high resolution
- study protocol
- atomic force microscopy
- weight loss
- double blind